28410389|t|Molecular subtyping of Treponema pallidum and associated factors of serofast status in early syphilis patients: Identified novel genotype and cytokine marker
28410389|a|Serofast, a persistent nontreponemal serological response observed in early syphilis patients after conventional treatment, remains a concern of clinicians and syphilis patients. No consensus has been established, however, that defines an effective treatment strategy and clarifies the pathogenesis. In this study, 517 patients with early syphilis were enrolled and treated. Twelve months after treatment, 79.3% (410/517) of patients achieved serological cure, 20.1% (104/517) were serofast, and 0.6% (3/517) were serological failures. Multivariate analysis demonstrated that older age (>40 years) and lower baseline RPR titer (â‰¤ 1:8) were associated with serofast status. We also identified 21 T. pallidum molecular subtypes among early syphilis patients and detected a new subtype, 14i/a. We found that the proportion of 14i/a type in serofast patients was significantly higher than that in patients with serological cure, predicting an increasing risk of serofast status. Levels of chemerin were higher in the serum of serofast cases than serological cure cases, potentially indicating a novel cytokine marker for serofast in early syphilis patients after therapy. We hope that these results contribute to improve guidelines for the management of syphilis patients who experience serofast.
28410389	0	19	Molecular subtyping	T059	C1294399
28410389	23	41	Treponema pallidum	T007	C0040840
28410389	46	64	associated factors	T169	C1521761
28410389	68	76	serofast	T033	C3841011
28410389	77	83	status	T080	C0449438
28410389	87	101	early syphilis	T047	C0348148
28410389	102	110	patients	T101	C0030705
28410389	112	122	Identified	T080	C0205396
28410389	129	137	genotype	T032	C0017431
28410389	142	150	cytokine	T116,T129	C0079189
28410389	151	157	marker	T201	C0005516
28410389	158	166	Serofast	T033	C3841011
28410389	170	180	persistent	T079	C0205322
28410389	181	206	nontreponemal serological	T169	C0205473
28410389	207	215	response	T201	C0521982
28410389	216	224	observed	T169	C1441672
28410389	228	242	early syphilis	T047	C0348148
28410389	243	251	patients	T101	C0030705
28410389	258	280	conventional treatment	T061	C2945704
28410389	292	299	concern	T078	C2699424
28410389	303	313	clinicians	T097	C0871685
28410389	318	326	syphilis	T047	C0348148
28410389	327	335	patients	T101	C0030705
28410389	397	406	effective	T080	C1704419
28410389	407	425	treatment strategy	T061	C0040808
28410389	430	439	clarifies	T052	C2986669
28410389	444	456	pathogenesis	T046	C0699748
28410389	466	471	study	T062	C2603343
28410389	477	485	patients	T101	C0030705
28410389	491	505	early syphilis	T047	C0348148
28410389	511	519	enrolled	T058	C1516879
28410389	524	531	treated	T169	C1522326
28410389	540	546	months	T079	C0439231
28410389	553	562	treatment	T061	C0087111
28410389	583	591	patients	T101	C0030705
28410389	601	612	serological	T169	C0205473
28410389	613	617	cure	T077	C1880198
28410389	640	648	serofast	T033	C3841011
28410389	672	683	serological	T169	C0205473
28410389	684	692	failures	T169	C0231174
28410389	694	715	Multivariate analysis	T081	C0026777
28410389	734	743	older age	T098	C1999167
28410389	749	754	years	T079	C0439234
28410389	766	774	baseline	T081	C1442488
28410389	775	784	RPR titer	T059	C3835799
28410389	798	813	associated with	T080	C0332281
28410389	814	822	serofast	T033	C3841011
28410389	823	829	status	T080	C0449438
28410389	853	864	T. pallidum	T007	C0040840
28410389	865	883	molecular subtypes	T185	C0449560
28410389	890	904	early syphilis	T047	C0348148
28410389	905	913	patients	T101	C0030705
28410389	933	947	subtype, 14i/a	T185	C0449560
28410389	981	991	14i/a type	T185	C0449560
28410389	995	1003	serofast	T033	C3841011
28410389	1004	1012	patients	T101	C0030705
28410389	1051	1059	patients	T101	C0030705
28410389	1065	1076	serological	T169	C0205473
28410389	1077	1081	cure	T077	C1880198
28410389	1097	1107	increasing	T169	C0442808
28410389	1108	1112	risk	T078	C0035647
28410389	1116	1124	serofast	T033	C3841011
28410389	1125	1131	status	T080	C0449438
28410389	1125	1131	status	T080	C0449438
28410389	1133	1139	Levels	T080	C0441889
28410389	1143	1151	chemerin	T116,T123	C1312957
28410389	1157	1163	higher	T080	C0205250
28410389	1171	1176	serum	T031	C0229671
28410389	1180	1188	serofast	T033	C3841011
28410389	1200	1211	serological	T169	C0205473
28410389	1212	1216	cure	T077	C1880198
28410389	1255	1263	cytokine	T116,T129	C0079189
28410389	1264	1270	marker	T201	C0005516
28410389	1275	1283	serofast	T033	C3841011
28410389	1287	1301	early syphilis	T047	C0348148
28410389	1302	1310	patients	T101	C0030705
28410389	1317	1324	therapy	T061	C0087111
28410389	1345	1352	results	T169	C1274040
28410389	1353	1363	contribute	T052	C1880177
28410389	1367	1374	improve	T033	C0184511
28410389	1375	1385	guidelines	T170	C0162791
28410389	1394	1404	management	T058	C0376636
28410389	1408	1416	syphilis	T047	C0348148
28410389	1417	1425	patients	T101	C0030705
28410389	1441	1449	serofast	T033	C3841011